CATALYST PHARMACEUTICALS, INC. 4

Steve Miller, Chief Operating & Scientific Officer of Catalyst Pharmaceuticals (CPRX), surrendered 1,093,803 common shares plus all outstanding stock options and RSUs for cash at the $31.50 per-share merger price in connection with the Angelini Pharma acquisition.

On July 15, 2026, Steve Miller, Chief Operating & Scientific Officer of Catalyst Pharmaceuticals, Inc., disposed of all his equity-based awards in connection with the cash acquisition of the company by Angelini Pharma S.p.A. at $31.50 per share. This included the cancellation of 1,093,803 shares of common stock at the $31.50 merger consideration, multiple tranches of stock options with exercise prices ranging from $3.42 to $22.77 per share, and several restricted stock unit (RSU) awards, all of which became fully vested at closing and were converted into the right to receive cash. For each option grant, Miller will receive cash equal to $31.50 minus the option exercise price, multiplied by the number of underlying shares, and for each RSU, he will receive $31.50 per unit, subject to taxes and deductions. Following these transactions, his equity holdings in Catalyst common stock, options, and RSUs were effectively reduced to zero, with all value realized in cash as part of the merger consideration.

Filing Facts

CIK

1369568

Ticker

CPRX

Form

4

Source Type

fda

Accession

0001161697-26-000180

Alert Tier

7